Sudeep Pharma Limited IPO Review
Neutral563-593 · Mainboard
✦
Analyst Verdict
Sudeep Pharma Limited IPO
Neutral
IPO at a Glance
Price Band
563-593
Issue Size
895cr
Min. Investment
₹14,825
Opens
2025-11-19
Closes
2025-11-23
Listing
2025-11-26
Category
Mainboard
Key Strengths
✓Strong R&D drives innovation and product advancement.
✓Experienced leadership with deep industry and functional expertise.
✓Advanced, compliant facilities with global certifications and scalable capacity.
✓Long-standing relationships with global blue-chip and Fortune 500 customers.
✓Market leader with a diversified portfolio in a high-entry-barrier ingredients industry.
Key Risks
⚠Top 10 customers contribute 35%+ of revenue, posing concentration risk.
⚠60%+ revenue from one segment poses concentration risk.
⚠Quality lapses or audit failures may lead to order loss and reputational harm.
⚠Operational concentration in Gujarat exposes the business to regional disruption risks.
⚠Delays or failures in new product launches may impact growth and profitability.
⚠Unsuccessful acquisitions may strain resources and dilute expected synergies.
⚠Regulatory and government approval delays may disrupt operations.
Frequently Asked Questions
Should I apply for Sudeep Pharma Limited IPO?
Based on our analysis, our rating for Sudeep Pharma Limited IPO is: Neutral. Review the full analysis including strengths, risks, and financials on CheckIPO before making a decision.
What are the key risks of Sudeep Pharma Limited IPO?
Top 10 customers contribute 35%+ of revenue, posing concentration risk. 60%+ revenue from one segment poses concentration risk. Quality lapses or audit failures may lead to order loss and reputational harm.
What are the strengths of Sudeep Pharma Limited IPO?
Strong R&D drives innovation and product advancement. Experienced leadership with deep industry and functional expertise. Advanced, compliant facilities with global certifications and scalable capacity.
What is the price band of Sudeep Pharma Limited IPO?
The price band for Sudeep Pharma Limited IPO is 563-593. The IPO has closed.
Full Analysis Available
Financials, DRHP breakdown, peer comparison, shareholding pattern & more